Foley Hoag Represents Pervasis Therapeutics in Deal With Shire
April 24, 2012
Foley Hoag LLP represented Pervasis Therapeutics in connection with a sale of substantially all of Pervasis’ assets to a subsidiary of Shire plc.
The deal provided Pervasis with an upfront payment, plus potential post-closing payments that are dependent on Shire’s achievement of certain clinical-development, regulatory and net-sales milestones. The U.K.-based Shire acquired Pervasis’ lead product Vascugel, which is currently in Phase 2 development for acute vascular repair, focused on improving hemodialysis access for patients with end-stage renal disease.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and investment management fields, and in cross-border disputes. Our professionals possess the skills and experience to provide exceptional senior level service to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.